Theranexus SA (FR:ALTHX) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Theranexus SA, a biopharmaceutical company, has reported a significant reduction in operating expenses for the first half of 2024, primarily due to the conclusion of a phase 1/2 clinical trial and a rigorous cost-cutting policy. This led to a considerable decrease in other purchases, external charges, and wage costs, resulting in a slight profit for the period compared to a loss in the previous year. The company’s cash position suggests operational activities funding is secure until at least the first quarter of 2025.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.